With respect to the current pandemic of new influenza A (H1N1): (a) who is at the top of the pandemic organizational chart for the country; (b) what gaps still exist in the government’s overarching plan, recognizing that it is an ever-evolving plan, and by what date will identified gaps be addressed; (c) what money remains from the $400 million contained in the budget of 2006 as ‘to be set aside as a contingency to be accessed on an as-needed basis’; (d) what funds have been spent since the start of the pandemic in Canada to address response, specifically, (i) what government departments have tested their pandemic plan, (ii) what departments operationalized their plans or part of their plans in the spring, and updated their plans since the lessons learned from the spring; (e) should there be an election, what is the pandemic preparedness plan for Elections Canada, both to protect the health and well-being of its employees and Canadians; (f) what are the outstanding issues among medical personnel in terms of preparedness, and how are these issues being addressed; (g) what was the process for monitoring swine herds prior to April 24, 2009, and how has it increased since that date; (h) what is the purpose behind the absence of a Canadian notifiable swine influenza surveillance system; (i) what is known of the clinical spectrum of the disease at this time, and what are the possible long-term impacts on lungs, and other organs, and potential long-term costs to the healthcare system; (j) by what date are provincial and territorial vaccine distribution plans to be in place, what oversight exists to ensure they are in place, and will they be made public; (k) what contingency plans are being put in place should Canadian distributors run out of stock of N95 masks; (l) will there be a compensation package should there be challenges with the vaccine; (m) what recommendations are being made to those with chronic conditions, such as cardiovascular disease, diabetes, and immunocompromised patients, and how is this information being relayed to these groups to see their doctor now; (n) what are the details of the “alternative strategies” being developed by provinces and territories; (o) what are the details of adding a “small amount of amantadine” to the National Emergency Stockpile System, and is its use in combination thought to be effective when the virus is resistant to amantadines; (p) are there any other alternative therapies being explored to address antiviral resistance and, if so, what funds are being allocated to the effort; (q) will 500 ventilators meet the potential intensive care unit (ICU) burden considering Canada’s ICU cases were around 20% of its hospitalized, compared to 15% in
In the House of Commons on November 16th, 2009. See this statement in context.